ESC: AstraZeneca’s Farxiga cuts kidney disease risks by 39% in trial that could ‘rewrite’ the treatment textbook kblankenship […]
ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha kblankenship Fri, 08/28/2020 – 18:15
Updated Date: Fri, 21 Aug 2020 00:00:00 EDT
Updated Date: Fri, 21 Aug 2020 00:00:00 EDT
Updated Date: Fri, 21 Aug 2020 00:00:00 EDT
Updated Date: Fri, 21 Aug 2020 00:00:00 EDT
Updated Date: Fri, 21 Aug 2020 00:00:00 EDT
ESC: Eli Lilly, Boehringer’s Jardiance cuts CV events by 25% in Farxiga-matching heart failure trial
ESC: Eli Lilly, Boehringer’s Jardiance cuts CV events by 25% in Farxiga-matching heart failure trial kblankenship Fri, 08/28/2020 […]
FiercePharmaAsia—Takeda’s $2.3B Japan consumer health sale; Bayer’s new Beijing plant; Celltrion’s latest biosim pact chelfand Fri, 08/28/2020 – […]
